BGLC vs AEYE

For growth investors, AudioEye, Inc.

(AEYE) is the stronger pick with 14. 5% revenue growth year-over-year, versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AudioEye, Inc.

(AEYE) delivered a total return of -57. 7%, compared to -98. 6% for BioNexus Gene Lab Corp. (BGLC). Over 10 years, the gap is even starker: AEYE returned +96. 5% versus BGLC's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioNexus Gene Lab Corp.

(BGLC) is the lower-risk stock at 1. 56β versus AudioEye, Inc. 's 2. 18β — meaning AEYE is approximately 40% more volatile than BGLC relative to the S&P 500. On balance sheet safety, BioNexus Gene Lab Corp. (BGLC) carries a lower debt/equity ratio of 3% versus 15% for AudioEye, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AudioEye, Inc.

(AEYE) is pulling ahead at 14. 5% versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). On earnings-per-share growth, the picture is similar: BioNexus Gene Lab Corp. grew EPS 41. 2% year-over-year, compared to 30. 6% for AudioEye, Inc.. Over a 3-year CAGR, AEYE leads at 10. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AudioEye, Inc.

(AEYE) is the more profitable company, earning -7. 6% net margin versus -16. 8% for BioNexus Gene Lab Corp. — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEYE leads at -7. 9% versus -16. 5% for BGLC. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioNexus Gene Lab Corp.

(BGLC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. AudioEye, Inc. (AEYE) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BGLC: -99. 2%, AEYE: +96. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BGLC (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.